Payment overview · 2025
General Payments
$425.88
23 reported records · 12 companies
Healthcare provider profile · identity verified
Heather Marks
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MEYERSDALE, PA · NPI 1366896342
Verified facts
What the public records show
CMS Open Payments records show Heather Marks received $425.88 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.38 | 20.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.38 | 14.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $53.26 | 12.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.47 | 10.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.15 | 9.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.73 | 7.2% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $26.65 | 6.3% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.13 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.13 | 4.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.07 | 3.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.50 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.03 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $425.88 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $60.38 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $53.26 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.47 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $41.15 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.38 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 159 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 150 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
150 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 618 | 133 |
| Lisinopril | Lisinopril | 515 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 382 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 349 | 68 |
| Omeprazole | Omeprazole | 310 | 63 |
| Losartan Potassium | Losartan Potassium | 297 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 251 | 52 |
| Furosemide | Furosemide | 245 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 239 | 50 |
| Gabapentin | Gabapentin | 208 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 50 |
| Montelukast Sodium | Montelukast Sodium | 176 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 37 |
| Potassium Chloride | Potassium Chloride | 167 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 35 |
| Simvastatin | Simvastatin | 160 | 35 |
| Eliquis | Apixaban | 159 | 29 |
| Jardiance | Empagliflozin | 150 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 43 |
| Metformin Hcl | Metformin Hcl | 142 | 34 |
| Alprazolam | Alprazolam | 138 | 42 |
| Lorazepam | Lorazepam | 133 | 45 |
| Metformin Hcl Er | Metformin Hcl | 115 | 29 |
| Sertraline Hcl | Sertraline Hcl | 115 | 27 |
| Trulicity | Dulaglutide | 94 | 18 |
| Carvedilol | Carvedilol | 90 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 15 |
| Synthroid | Levothyroxine Sodium | 84 | 19 |
| Ozempic | Semaglutide | 81 | 17 |
| Celecoxib | Celecoxib | 80 | 14 |
| Famotidine | Famotidine | 79 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 18 |
| Alendronate Sodium | Alendronate Sodium | 77 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 22 |
| Mounjaro | Tirzepatide | 67 | 11 |
| Allopurinol | Allopurinol | 66 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 15 |
| Atenolol | Atenolol | 64 | 12 |
| Xarelto | Rivaroxaban | 62 | 11 |
| Buspirone Hcl | Buspirone Hcl | 61 | 14 |
| Glimepiride | Glimepiride | 60 | 13 |
| Trazodone Hcl | Trazodone Hcl | 59 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 13 |
| Ezetimibe | Ezetimibe | 58 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 58 | 27 |
| Prednisone | Prednisone | 56 | 47 |
| Bumetanide | Bumetanide | 54 | 12 |
| Meloxicam | Meloxicam | 54 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | suppressed |
| Cephalexin | Cephalexin | 50 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Methylprednisolone | Methylprednisolone | 48 | 37 |
| Clonazepam | Clonazepam | 47 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 12 |
| Baclofen | Baclofen | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Pregabalin | Pregabalin | 42 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Valsartan | Valsartan | 39 | 15 |
| Finasteride | Finasteride | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 14 |
| Tradjenta | Linagliptin | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 23 |
| Sucralfate | Sucralfate | 27 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 18 |
| Jantoven | Warfarin Sodium | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 11 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 13 |
| Acyclovir | Acyclovir | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Toprol Xl | Metoprolol Succinate | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $425.88 · 23 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, OTEZLA, Ozempic, PREVNAR 20, REPATHA, RINVOQ, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VYEPTI, Wegovy, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error